Warning Letter — Eherbs Imports, Inc
The FDA issued a Warning Letter to Eherbs Imports, Inc. following an assessment by the Office of Inspections and Investigations.
This action affects Eherbs Imports, Inc., as well as its internal departments responsible for regulatory compliance, labeling oversight, and import management.
The issuance of a Warning Letter by the Office of Inspections and Investigations typically indicates significant deviations from federal regulations, often involving product labeling or manufacturing standards. While the source does not detail specific violations, such letters usually signal that the firm's responses to previous inspectional observations were insufficient, potentially leading to import alerts or further enforcement if not remediated. Regulatory teams should interpret this as a requirement for immediate corrective action regarding the firm's compliance posture.
Regulatory and QA teams should conduct a comprehensive review of all product labeling and promotional claims to ensure no unapproved drug claims are being made. Compliance officers should verify that foreign supplier documentation and import records align with current FDA registration and listing requirements.
FDA Warning Letter issued to: Eherbs Imports, Inc. 07/23/2026 — Office of Inspections and Investigations. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eherbs-imports-inc-732692-07232026
Open in openFDA / FDA.gov